Clinical

Clinical
Pfizer announced positive data from TALAPRO-2 trial

Prostate Cancer -Feb 2023 Prostate Cancer – Feb 2023 16 Feb 2023: Talazoparib + Enzalutamide (Oral) / Pfizer: Positive data from TALAPRO-2 trial for 1L mCRPC; Priority review from US FDA granted Summary: Initial data show 37% reduction in risk […]

by Sandhya Ramalingam

Continue Reading
Clinical
AstraZeneca presented Phase 3 OS results from PROpel trial

Prostate Cancer -Feb 2023 Prostate Cancer – Feb 2023 16 Feb 2023: Olaparib + Abiraterone (Oral) / AstraZeneca: Overall survival results from Phase 3 PROpel trial presented at ASCO GU 2023 Summary: The Olaparib + Abiraterone combo posted a median […]

by Sandhya Ramalingam

Continue Reading